

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A03/2014

DESPATCHED ON 25TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A30; B18, B57; Cw5, Cw6; DR7, DR17; DQ2, DQ9

Summary of Results					Summary of Results			
Total tested	21	21	20	21	16	16	15	16
Positive	1	19	1	18	1	14	1	0
Negative	20	2	19	3	15	2	14	16
Not Tested	2	2	3	2	0	0	1	0
% Positive	4.8%	90.5%	5.0%	85.7%	6.3%	87.5%	6.7%	0.0%
% Negative	95.2%	9.5%	95.0%	14.3%	93.8%	12.5%	93.3%	100.0%
Consensus	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative
HLA Antibody (Defined By CDC)	DR3	B14+	DR3	A2, B17				

Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Negative	NT	Positive	Negative	Negative	NT	Negative	Not tested due to low cell count
11	Negative	Positive	Negative	Positive					
12	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
14	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
15	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
19	Negative	Negative	Negative	Positive					
20	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
23	Negative	Positive	Negative	Positive					
24	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
25	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
28	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
34	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
35	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	
38	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
39	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
41	NT	NT	NT	NT					Poor sample quality
42	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
45	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
48	NT	NT	NT	NT					Samples delayed in post and cells not viable
51	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
54	Negative	Positive	Negative	Positive					
58	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	
62	Negative	Positive	Negative	Positive					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A03/2014

DESPATCHED ON 25TH MARCH 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
9	0	0	NT	4	0	0	NT	0	27-Mar	28-Mar	Yes	Yes	90	Cedarlane	30	30	AO/PI	
11		4		8					26-Mar	27-Mar	Yes	Yes	95	Cedarlane	45	90	Fluoroquench	
12	5%	95%	5%	95%	5%	95%	5%	10%	26-Mar	26-Mar	Yes	Yes	95	Cedarlane	30	90	EB/AO	
14	0	8	0	6	0	8	0	0	26-Mar	26-Mar	Yes	Yes	90	Cedarlane	60	120	EB/AO	
15		2		6		4			26-Mar	26-Mar	Yes	Yes	95	Cedarlane	60	60	EB/AO	
19	0	0	0	9					26-Mar	27-Mar	Yes	No	100	Cedarlane	30	120	CFDA/EB	
20	1	6	1	8	1	9	1	1	26-Mar	26-Mar	Yes	Yes	90	Cedarlane	30	60	EB/AO	
23	1	8	1	8					26-Mar	26-Mar	Yes	Yes	90	Cedarlane	40	40	EB/AO	
24	5	100	10	100	20	100	15	25	26-Mar	27-Mar	Yes	Yes	90	Cedarlane	45	90	EB/AO	
25	1	8	1	6	1	8	1	1	26-Mar	27-Mar	Yes	Yes	99	Cedarlane	45	60	Fluoroquench	
28	1	6	1	2	1	6	1	1	26-Mar	26-Mar		Yes		Cedarlane	30	45	EB/AO	
34	1	6	1	8	1	8	1	1	26-Mar	26-Mar	Yes	Yes	99	Cedarlane	30	90	EB/AO	
35	1	6	1	1	1	1	1	1	26-Mar	27-Mar	Yes	Yes	80	70	Cedarlane	45	90	Fluoroquench
38	2	8	2	8	2	4	2	1	26-Mar	26-Mar	Yes	Yes	90	95	Cedarlane	60	60	EB/AO
39		4				2			26-Mar	26-Mar	Yes	No	95	Cedarlane	45	90	EB/AO	
41	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	27-Mar	Yes	No	60	Cedarlane	60	60	EB/AO	
42		80-100%		80-100%		80-100%			26-Mar	27-Mar	Yes	No	95	TCS Biosciences	60	120	EB/AO	
45	1	8	1	8	1	8	1	1	26-Mar	27-Mar	Yes	Yes	99	Cedarlane	60	90	EB/AO	
48	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	28-Mar	NT	NT	NT	NT	NT	NT	NT	
51	0	8	0	0	0	8	0	0	27-Mar	28-Mar	Yes	Yes	90	Cedarlane	60	60	Fluoroquench	
54	<5%	80-90%	<5%	>90%					26-Mar	27-Mar	Yes	Yes	>95	Cedarlane	60	60	PI	
58	5%	60%	5%	99%	5%	99%	5%	5%	26-Mar	26-Mar	Yes	Yes	95	Cedarlane	60	90	Fluoroquench	
62	1	8	1	8					26-Mar	26-Mar	Yes	Yes	90	Cedarlane	60	120	EB/AO	

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A03/2014

DESPATCHED ON 25TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A30; B18, B57; Cw5, Cw6; DR7, DR17; DQ2, DQ9

Summary of Results					Summary of Results				
Total tested	19	19	20	19	14	14	14	14	
Positive	19	15	20	19	14	13	14	2	
Negative	0	4	0	0	0	1	0	12	
Not Tested	3	3	2	3	0	0	0	0	
% Positive	100.0%	78.9%	100.0%	100.0%	100.0%	92.9%	100.0%	14.3%	
% Negative	0.0%	21.1%	0.0%	0.0%	0.0%	7.1%	0.0%	85.7%	
Consensus	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
HLA Antibody (Defined By CDC)	DR3	B14+	DR3	A2, B17					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	NT	NT	Positive	NT					Not tested due to low cell count
11	Positive	Negative	Positive	Positive					
12	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Serum 2 positive at dilution, negative when neat
14	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	
15	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
19	Positive	Positive	Positive	Positive					
20	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
23	Positive	Positive	Positive	Positive					Poor sample quality
24	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
25	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
28	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	
34	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
38	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Samples delayed in post and cells not viable
39	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
41	NT	NT	NT	NT					
42	Positive	Positive	Positive	Positive	Positive	Weak Positive	Positive	Negative	
45	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
48	NT	NT	NT	NT					
51	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	
54	Positive	Negative	Positive	Positive					
58	Positive	Negative	Positive	Positive	Positive	Positive	Positive	Negative	
62	Positive	Positive	Positive	Positive					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A03/2014

DESPATCHED ON 25TH MARCH 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9			8						27-Mar	28-Mar	Yes	90	Cedarlane	30	30	AO/PI
11	4		8	8					26-Mar	27-Mar	Yes	95	Cedarlane	45	90	Fluoroquench
12	50%	60%	95%	90%	50%	60%	95%	5%	26-Mar	26-Mar	Yes	90	Cedarlane	30	60	EB/AO
14	8	8	8	8	8	8	8	2	26-Mar	26-Mar	Yes	90	Cedarlane	60	120	EB/AO
15	6	4	6	6	6	4	6		26-Mar	26-Mar	Yes	95	Cedarlane	60	60	EB/AO
19	9	8	9	9					26-Mar	27-Mar	Yes	100	Cedarlane	30	90	CFDA/EB
20	8	8	9	9	8	9	9	1	26-Mar	26-Mar	Yes	60	Cedarlane	30	60	EB/AO
23	8	8	8	8					26-Mar	26-Mar	Yes	90	Cedarlane	40	40	EB/AO
24	100	80	100	95	100	95	100	35	26-Mar	27-Mar	Yes	90	Cedarlane	45	90	EB/AO
25	8	1	8	4	8	1	4	1	26-Mar	27-Mar	Yes	99	Cedarlane	45	60	Fluoroquench
28	8	8	8	8	8	8	8	4	26-Mar	26-Mar	Yes		Cedarlane	30	45	EB/AO
34	8	4	8	8	8	8	8	1	26-Mar	26-Mar	Yes	90	Cedarlane	30	90	EB/AO
38	8	6	8	8	8	8	8	1	26-Mar	26-Mar	Yes	90	Cedarlane	60	60	EB/AO
39	4	4	6	8	2	4	6		26-Mar	26-Mar	Yes	95	Cedarlane	45	90	EB/AO
41	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	27-Mar	Yes	50	Cedarlane	45	45	EB/AO
42	80-100%	40-60%	80-100%	80-100%	80-100%	20-40%	80-100%		26-Mar	27-Mar	Yes	95	TCS Biosciences	60	60	EB/AO
45	8	4	8	8	8	8	8	1	26-Mar	27-Mar	Yes	90	Cedarlane	30	75	EB/AO
48	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	28-Mar	NT	NT	NT	NT	NT	NT
51	8	6	8	2	8	6	8	0	27-Mar	28-Mar	Yes	90	Cedarlane	60	60	Fluoroquench
54	>90%	5-10%	>90%	>90%					26-Mar	27-Mar	Yes	>90	Cedarlane	60	60	PI
58	100%	5%	100%	100%	100%	95%	100%	5%	26-Mar	26-Mar	Yes	95	Cedarlane	60	90	Fluoroquench
62	6	6	6	6					26-Mar	26-Mar	Yes	70	One Lambda	60	120	EB/AO

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate